Clinical Trial

MegaNatural BP® GSE on Blood Pressure and Cardiometabolic Risk Factors

Study acronym: GSEBP
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 15, 2025 (before its estimated July 22, 2026 completion). Its status may not reflect the trial's current state.
Summary
Inflammation and stressors can interfere with the function of the lining of blood vessels and insulin activity, therefore, investigators are aiming to see how the Grape seed Extract (GSE) called MegaNatural BP can help with limiting the effects of these factors. This research will study the effects of taking 150mg of MegaNatural BP GSE per day on blood pressure levels along with influences on heart health through assessing the function of the blood vessel lining and levels of inflammation.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-08-13; most recent amendment 2025-07-10.
Trial Details
NCT Number NCT06555952
Lead Sponsor Clinical Nutrition Research Center, Illinois Institute of Technology
Conditions Hypertension, Pre Diabetes
Enrollment 80 participants
Start Date 2024-08-08
Primary Completion 2026-07-22 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-15